|
Q4 FY2025
As of Dec 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
|
|---|---|---|---|---|
| Current assets | ||||
| Cash and cash equivalents | ||||
| Consummative biological assets | ||||
| Accounts receivable | ||||
| Consumptive biological assets | ||||
| Inventories | ||||
| Other receivables | ||||
| Prepaid taxes | ||||
| Other current assets | ||||
| Total current assets | ||||
| Property and equipment, net | ||||
| Operating lease right-of-use assets | ||||
| Deferred tax assets | ||||
| Other assets | ||||
| Total assets | ||||
| Current liabilities | ||||
| Accounts payable and accrued liability | ||||
| Accounts payable | ||||
| Accrued expenses | ||||
| Income tax payable | ||||
| Other payable | ||||
| Due to related parties | ||||
| Related party | ||||
| Total due to related parties | ||||
| Advance receipts | ||||
| Other current liabilities | ||||
| Operating lease liabilities – current portion | ||||
| Long-term loans payable – current portion | ||||
| Total current liabilities | ||||
| Long-term loans payable | ||||
| Operating lease liabilities – noncurrent portion | ||||
| Total Liabilities | ||||
| Stockholders’ deficit | ||||
| Ordinary shares, $0.0001 par value, 500,000,000 shares authorized, 111,120,000 shares issued and outstanding as of December 31, 2025 and 2024 | ||||
| Additional paid-in capital | ||||
| Accumulated deficit | ||||
| Accumulated other comprehensive income | ||||
| Total stockholders’ deficit | ||||
| Total liabilities and stockholders’ deficit | ||||
Loading...
